Key Publications



To download a PDF version, please click on the title of the desired publication


Midkine for detecting cancer

2010

Jono, H. & Ando, Y. Midkine: A Novel Prognostic Biomarker for Cancer. Cancers, 2, 624-641.

2009

Ibusuki, M., Fujimori, H., Yamamoto, Y., Ota, K., Ueda, M., Shinriki, S., Taketomi, M., Sakuma, S., Shinohara, M., Iwase, H. & Ando, Y. Midkine in plasma as a novel breast cancer marker. Cancer Sci, 100, 1735-9.

2008

Ikematsu, S., Nakagawara, A., Nakamura, Y., Ohira, M., Shinjo, M., Kishida, S. & Kadomatsu, K. Plasma midkine level is a prognostic factor for human neuroblastoma. Cancer Sci, 99, 2070-4.

2003

Ikematsu, S., Nakagawara, A., Nakamura, Y., Sakuma, S., Wakai, K., Muramatsu, T. & Kadomatsu, K. Correlation of elevated level of blood midkine with poor prognostic factors of human neuroblastomas. Br J Cancer, 88, 1522-6.

2000

Ikematsu, S., Yano, A., Aridome, K., Kikuchi, M., Kumai, H., Nagano, H., Okamoto, K., Oda, M., Sakuma, S., Aikou, T., Muramatsu, H., Kadomatsu, K. & Muramatsu, T. Serum midkine levels are increased in patients with various types of carcinomas. Br J Cancer, 83, 701-6.



Midkine and acute myocardial infarction

2009

Takenaka, H., Horiba, M., Ishiguro, H., Sumida, A., Hojo, M., Usui, A., Akita, T., Sakuma, S., Ueda, Y., Kodama, I. & Kadomatsu, K. Midkine prevents ventricular remodeling and improves long-term survival after myocardial infarction. Am J Physiol Heart Circ Physiol, 296, 462-9.

2007

Ishiguro, H., Takenaka, H., Sumida, A., Kadomatsu, K., Murohara, T., Kodama, I. & Horiba, M. Abstract 1062: A Single Intracoronary Injection of Midkine Reduces Ischemia/reperfusion Injury in Swine Hearts: A Novel Therapeutic Approach for Acute Coronary Syndrome. Circulation, 116, 11_212.

2006

Horiba, M., Kadomatsu, K., Yasui, K., Lee, J. K., Takenaka, H., Sumida, A., Kamiya, K., Chen, S., Sakuma, S., Muramatsu, T. & Kodama, I. Midkine plays a protective role against cardiac ischemia/reperfusion injury through a reduction of apoptotic reaction. Circulation, 114, 1713-20.



Midkine and inflammatory disease

2008

Wang, J., Takeuchi, H., Sonobe, Y., Jin, S., Mizuno, T., Miyakawa, S., Fujiwara, M., Nakamura, Y., Kato, T., Muramatsu, H., Muramatsu, T. & Suzumura, A. Inhibition of midkine alleviates experimental autoimmune encephalomyelitis through the expansion of regulatory T cell population. Proc Natl Acad Sci U S A, 105, 3915-20.

2007

Kosugi, T., Yuzawa, Y., Sato, W., Arata-Kawai, H., Suzuki, N., Kato, N., Matsuo, S. & Kadomatsu, K. Midkine is involved in tubulointerstitial inflammation associated with diabetic nephropathy. Lab Invest, 87, 903-13.

2005

Sato, W., Takei, Y., Yuzawa, Y., Matsuo, S., Kadomatsu, K. & Muramatsu, T. Midkine antisense oligodeoxyribonucleotide inhibits renal damage induced by ischemic reperfusion. Kidney Int, 67, 1330-9.

2004

Maruyama, K., Muramatsu, H., Ishiguro, N. & Muramatsu, T. Midkine, a heparin-binding growth factor, is fundamentally involved in the pathogenesis of rheumatoid arthritis. Arthritis Rheum, 50, 1420-9.

1997

Takada, T., Toriyama, K., Muramatsu, H., Song, X. J., Torii, S., Muramatsu, T. Midkine, a retinoic acid-inducible heparin-binding cytokine in inflammatory responses: chemotactic activity to neutrophils and association with inflammatory synovitis. J Biochem, 122, 453-8.



General midkine biology

2010

Muramatsu, T. Midkine, a heparin-binding cytokine with multiple roles in development, repair and diseases. Proceedings of the Japan Academy, Series B, 86, 410-425.

2004

Kadomatsu, K. & Muramatsu, T. Midkine and pleiotrophin in neural development and cancer. Cancer Lett, 204, 127-43.

2004

Ohuchida, T., Okamoto, K., Akahane, K., Higure, A., Todoroki, H., Abe, Y., Kikuchi, M., Ikematsu, S., Muramatsu, T. & Itoh, H. Midkine protects hepatocellular carcinoma cells against TRAIL-mediated apoptosis through down-regulation of caspase-3 activity. Cancer, 100, 2430-6.

2002

Muramatsu, T. Midkine and pleiotrophin: two related proteins involved in development, survival, inflammation and tumorigenesis. J Biochem, 132, 359-71.